Valuation
- Market cap
- 6,350,000
- Revenue TTM
- $0
- Net income TTM
- $-11,630,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 324,700
- Avg volume
- 6,310,936
- Day's range
- $0.74 – $0.81
- Shares out
- 8,190,000
- Stochastic %K
- 2%
- Beta
- 2.32
- Analysts
- Strong Buy
- Price target
- —
Company profile
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowe...
Show more
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
- Industry
- Computer Hardware
- Sector
- Technology
- Phone
- 856 848 8698
- Website
- https://www.qctechnologies.com
- Address
- 1185 Avenue of the Americas, Suite 249, New York, United States
Latest news
No headlines yet.
